The Administrative Core will provide central leadership and management for the Oklahoma Autoimmunity Center of Excellence (Oklahoma ACE) to expedite translation of basic science advances to clinical application in the diagnosis and treatment of systemic autoimmune diseases. Coordinating the efforts of key participants from adult and pediatric rheumatology, adult and pediatric endocrinology, neurology, hematology, dermatology, dentistry, ophthalmology, and a variety of basic science disciplines such as various types of immunology, molecular biology, genetics, biostatistics, and epidemiology will be one of the central missions of this Core. Providing unique trans-disciplinary opportunities to discuss translational autoimmune disease research through the Autoimmunity Forums, as well as coordinating participation in ACE led clinical trials will be the focus of this Oklahoma ACE. These tasks will include (i) acting on behalf of the Oklahoma ACE member institutions, and within the ACE Network and NIH Program, (ii) ensuring fiscal responsibility for all components of the ACE, and (iii) providing an educational foundation for a multidisciplinary approach to autoimmune disease research. The Administrative Core Leader will perform the daily management tasks, host monthly Autoimmunity Forums, and facilitate annual EAB meetings. The Core Leader will also meet monthly with the Clinical Representative to ensure the Clinical Center needs are being met. The Core Leader will serve as the primary contact within the ACE Network and with the assistance of the Clinical Representative coordinate sample distribution both within the Oklahoma ACE community and the ACE Network. The Core Leader and Clinical Representative will attend ACE Steering Committee meetings. The Core Leader will also be the primary contact for the NIH ACE Program. She will be responsible for preparing and submitting all annual progress reports, and just-in-time and other information as needed to the NIH. Through the assistance of the OMRF grants accounting office, the Core Leader will also be responsible for managing the Oklahoma ACE budget. These services provided by the Administrative Core will optimize use of the funding to ensure the Oklahoma ACE goals are met in a timely manner.

Public Health Relevance

The Oklahoma ACE community is a multidisciplinary team of clinician scientists and basic science investigators with the common goal of improving the lives of patients with systemic autoimmune diseases through expediting the translation of basic science findings to clinical applications. The Administrative Core will provide the central leadership and management to the Oklahoma ACE community.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI082714-05
Application #
8461115
Study Section
Special Emphasis Panel (ZAI1-QV-I)
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
5
Fiscal Year
2013
Total Cost
$127,918
Indirect Cost
$82,573
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Fayyaz, Anum; Kurien, Biji T; Scofield, R Hal (2016) Autoantibodies in Sjögren's Syndrome. Rheum Dis Clin North Am 42:419-34
Arriens, Cristina; Chen, Sixia; Karp, David R et al. (2016) Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin Immunol :
Ward, Julie M; Ratliff, Michelle L; Dozmorov, Mikhail G et al. (2016) Expression and methylation data from SLE patient and healthy control blood samples subdivided with respect to ARID3a levels. Data Brief 9:213-9
Sandhya, Pulukool; Kurien, Biji Theyilamannil; Danda, Debashish et al. (2016) Update on Pathogenesis of Sjögren's syndrome. Curr Rheumatol Rev :
Young, Kendra A; Munroe, Melissa E; Guthridge, Joel M et al. (2016) Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus. Ann Rheum Dis :
Lu, Rufei; Munroe, Melissa E; Guthridge, Joel M et al. (2016) Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J Autoimmun 74:182-193
Alarcón-Riquelme, Marta E; Ziegler, Julie T; Molineros, Julio et al. (2016) Genome-Wide Association Study in an Amerindian Ancestry Population Reveals Novel Systemic Lupus Erythematosus Risk Loci and the Role of European Admixture. Arthritis Rheumatol 68:932-43
Liu, Ke; Kurien, Biji T; Zimmerman, Sarah L et al. (2016) X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. Arthritis Rheumatol 68:1290-300
Ward, Julie M; Ratliff, Michelle L; Dozmorov, Mikhail G et al. (2016) Human effector B lymphocytes express ARID3a and secrete interferon alpha. J Autoimmun 75:130-140
Harris, Valerie M; Sharma, Rohan; Cavett, Joshua et al. (2016) Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. Clin Immunol 168:25-9

Showing the most recent 10 out of 105 publications